Blood Component Therapy in the Critically Ill
Blood component therapy remains one of the greatest advances in modern medicine. It has not only been a major contribution to survival from hemorrhagic shock, but has also allowed complex surgery to develop and specific congenital and acquired hemopoeitic deficiency states to be temporarily corrected. Blood component therapy is one of the most important ‘weapons’ in the intensivist’s armentarium . It is important that critical care physicians clearly understand the diagnosis and management of hemopoeitic defects, the composition of the various blood components and to carefully analyse the risk/benefit equation in the use of blood products. The correctly identified, appropriately administered and timely blood component can be lifesaving. It should, however, be emphasized that blood component therapy is similar to many aspects of critical care medicine where interim support is being provided for the patient to survive a potentially lethal organ malfunction, in order for other appropriate corrective medical therapy or surgery to be applied and for the body’s host defense system to initiate its appropriate responses and establish healing. In some circumstances, the basic underlying pathophysiology for the patient’s illness may be poorly understood and a definitive diagnosis may not have been made.
KeywordsToxicity Depression Lactate Citrate Anemia
Unable to display preview. Download preview PDF.
- 1.Isbister JP (1985) Blood component therapy in clinical medicine. Blackwell, MelbourneGoogle Scholar
- 2.Insalaco S, Menitove J (1987) Transfusion-transmitted viruses: Epidemiology and pathology. Am Assoc of Blood BanksGoogle Scholar
- 5.Isbister JP (1984) Blood transfusion and blood component therapy. Clin Anesth 2:643–666Google Scholar
- 10.National Institute of Health Bethesda, MD (1987): Platelet transfusion therapyGoogle Scholar
- 16.Wu HS, Little AG (1988) Perioperative blood transfusions and cancer recurrence. J Clin Onco 6:1348–1354Google Scholar